A new scientific article has been published
Date: 2023-01-04
In the prestigious journal Alzheimer's Research & Therapy, Alzinova presents preclinical results demonstrating that the ALZ-201 antibody has specificity for the toxic oligomers that are central to the onset and development of Alzheimer's disease.
Furthermore, the research shows that ALZ-201 has the potential to be “best-in-class” in the clinic with good efficacy and more favourable side-effect profile compared to other candidates.
Link to Alzheimer’s Research & Therapy article